The next step is to run clinical trials of DCA in people with cancer. These may have to be funded by charities, universities and governments: pharmaceutical companies are unlikely to pay because they can’t make money on unpatented medicines.
Untrue. In fact, that's absurd on its face. The pharmaceutical industry is all about the patents, and nothing else.Cancer cure is worth HUGE profit whether it's patented or not.
Which brings back up my point, how much does the medical profession really want a cheap easy cure for cancer ?
besides, that would free huge resources up for cures for other diseases, which wouldn't be any less profitable that cancer work is now.
if what youare saying was true, then we wouldn't have antibiotics, poloi, mumps, etc cures, since it's more profitable to treat the symtoms than cure the disease; and tha, historically, has NOT happened at all.
As the article says, it seems too good to be true.If it is indeed ready for a Clinical Phase I trial, this work is tailor-made for NIH-NCI (National Cancer Institute). The side effects are a serious concern because it will be important to determine what's causing them; in other words is the effect of the drug really as specific against cancer as the article suggests?
If this is real, it's fantastic. There might be some concern among the administration of cancer hospitals about their futures, but I can't believe that they could get away with any efforts to stall this research, not when literally millions of lives may be at stake. My sister is a nurse and works partly at the cancer hospital in Toronto; I know that she and her colleagues would be delighted not to see their patients dying. They won't be out of work; their skills are still valid elsewhere.